Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations

[1]  J. Jordan,et al.  A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative. , 2014, Seminars in arthritis and rheumatism.

[2]  R. Dworkin,et al.  EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial , 2014, The Lancet.

[3]  J. Farrar,et al.  Interpreting patient treatment response in analgesic clinical trials: Implications for genotyping, phenotyping, and personalized pain treatment , 2014, PAIN®.

[4]  L. Kux.  OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[5]  C. Wade,et al.  An innovative acupuncture treatment for primary dysmenorrhea: a randomized, crossover pilot study. , 2014, Alternative therapies in health and medicine.

[6]  R. Freeman,et al.  Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus , 2013, PAIN®.

[7]  R. Gross.  Spotlight on the July 2 Issue , 2013, Neurology.

[8]  M. Rowbotham,et al.  Assay sensitivity and study features in neuropathic pain trials , 2013, Neurology.

[9]  Blair H. Smith,et al.  Can pragmatic trials help us better understand chronic pain and improve treatment? , 2013, Pain.

[10]  R. Shelton,et al.  A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. , 2012, The Journal of clinical psychiatry.

[11]  R. Little,et al.  The design and conduct of clinical trials to limit missing data , 2012, Statistics in medicine.

[12]  Elizabeth D. Dalton,et al.  L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. , 2012, The American journal of psychiatry.

[13]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[14]  D. Grobbee,et al.  Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: Application to antidepressant trials , 2012, Clinical trials.

[15]  T. Smart,et al.  An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee , 2012, PAIN®.

[16]  D. Price,et al.  Viscerosomatic facilitation in a subset of IBS patients, an effect mediated by N-methyl-D-aspartate receptors. , 2012, The journal of pain : official journal of the American Pain Society.

[17]  T. Smart,et al.  Efficient assessment of efficacy in post-traumatic peripheral neuropathic pain patients: pregabalin in a randomized, placebo-controlled, crossover study , 2012, Journal of pain research.

[18]  F. Miller,et al.  Early phase drug development for treatment of chronic pain--options for clinical trial and program design. , 2012, Contemporary clinical trials.

[19]  M. Rowbotham,et al.  Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations , 2012, PAIN.

[20]  K. Bär,et al.  [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]. , 2012, Schmerz.

[21]  M. Rowbotham,et al.  Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain , 2012, PAIN®.

[22]  Gordon Guyatt,et al.  American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee , 2012, Arthritis care & research.

[23]  C. Eccleston,et al.  Estimate at your peril: Imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses , 2012, PAIN.

[24]  M. Pencina,et al.  A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study) , 2012, Psychotherapy and Psychosomatics.

[25]  F. Petzke,et al.  Medikamentöse Therapie des Fibromyalgiesyndroms , 2008, Der Schmerz.

[26]  Robert L. Becker,et al.  Contains Nonbinding Recommendations Draft – Not for Implementation Guidance for Industry Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products , 2012 .

[27]  W. Rief,et al.  Mechanisms Involved in Placebo and Nocebo Responses and Implications for Drug Trials , 2011, Clinical pharmacology and therapeutics.

[28]  Erik Olofsen,et al.  Pharmacokinetic–pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature , 2011, Expert review of clinical pharmacology.

[29]  C. Birbara,et al.  Efficacy and safety of tanezumab in the treatment of chronic low back pain , 2011, PAIN®.

[30]  L. Aarts,et al.  Absence of long‐term analgesic effect from a short‐term S‐ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo‐controlled trial , 2011, European journal of pain.

[31]  K. Bley,et al.  Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch , 2011, British journal of anaesthesia.

[32]  R. Kravitz,et al.  N-of-1 Trials in the Medical Literature: A Systematic Review , 2011, Medical care.

[33]  B. Schachtel,et al.  Efficacy of low-dose celecoxib in patients with acute pain. , 2011, The journal of pain : official journal of the American Pain Society.

[34]  Malcolm Rowland,et al.  Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response , 2011, Nature Reviews Drug Discovery.

[35]  M. Magnin,et al.  On the importance of placebo timing in rTMS studies for pain relief , 2011, PAIN.

[36]  Wendy R. Sanhai,et al.  Evidence-based clinical trial design for chronic pain pharmacotherapy: A blueprint for ACTION , 2011, PAIN.

[37]  B. Galer,et al.  Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain , 2011, PAIN®.

[38]  S. Daniels,et al.  A randomised, five-parallel-group, placebo-controlled trial comparing the efficacy and tolerability of analgesic combinations including a novel single-tablet combination of ibuprofen/paracetamol for postoperative dental pain , 2011, PAIN®.

[39]  Marieke Niesters,et al.  Population pharmacokinetic—pharmacodynamic modeling of ketamine‐induced pain relief of chronic pain , 2011, European journal of pain.

[40]  T. Fleming.  Addressing Missing Data in Clinical Trials , 2011, Annals of Internal Medicine.

[41]  Blair H. Smith,et al.  NeuPSIG guidelines on neuropathic pain assessment , 2011, PAIN®.

[42]  E. Irvin,et al.  A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. , 2011, Pain research & management.

[43]  R. Temple,et al.  Enrichment of Clinical Study Populations , 2010, Clinical pharmacology and therapeutics.

[44]  C. Eccleston,et al.  “Evidence” in chronic pain – establishing best practice in the reporting of systematic reviews , 2010, PAIN.

[45]  T. Nurmikko,et al.  EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision , 2010, European journal of neurology.

[46]  Christine M. Micheel,et al.  Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .

[47]  Richard E. White,et al.  Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations , 2010, PAIN®.

[48]  F. Johnson,et al.  ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. , 2010, The journal of pain : official journal of the American Pain Society.

[49]  R. Treede,et al.  Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update SUPPLEMENT ARTICLE , 2010 .

[50]  Nathaniel Katz.  Enriched Enrollment Randomized Withdrawal Trial Designs of Analgesics: Focus on Methodology , 2009, The Clinical journal of pain.

[51]  D. Tu,et al.  Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial , 2009, The Lancet.

[52]  J. Markenson,et al.  Efficacy of combined local mechanical vibrations, continuous passive motion and thermotherapy in the management of osteoarthritis of the knee. , 2009, Osteoarthritis and cartilage.

[53]  Donald A. Berry,et al.  Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .

[54]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[55]  Ian Harvey,et al.  A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers , 2009, Canadian Medical Association Journal.

[56]  Michael A Proschan,et al.  Sample size re‐estimation in clinical trials , 2009, Biometrical journal. Biometrische Zeitschrift.

[57]  F. Vaida,et al.  Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial , 2009, Neuropsychopharmacology.

[58]  T. Ho,et al.  Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies , 2009, PAIN®.

[59]  H. Kraemer,et al.  The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. , 2008, The Journal of clinical psychiatry.

[60]  M. Rowbotham,et al.  Placebo response in neuropathic pain trials , 2008, PAIN.

[61]  S. Straube,et al.  Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. , 2008, British journal of clinical pharmacology.

[62]  Christopher L. Wu,et al.  Morphine versus Mexiletine for Treatment of Postamputation Pain: A Randomized, Placebo-controlled, Crossover Trial , 2008, Anesthesiology.

[63]  L. Lasagna,et al.  Do "placebo responders" exist? , 2008, Contemporary clinical trials.

[64]  D. Price,et al.  Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: How study designs can affect placebo factors , 2008, PAIN.

[65]  S. Fishman,et al.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. , 2008, The journal of pain : official journal of the American Pain Society.

[66]  Anastasia Ivanova,et al.  Adaptive dose finding based on t‐statistic for dose–response trials , 2008, Statistics in medicine.

[67]  Shein-Chung Chow,et al.  Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.

[68]  R. Jamison,et al.  Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. , 2008, The journal of pain : official journal of the American Pain Society.

[69]  R. Moore,et al.  Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain , 2008, PAIN.

[70]  E Jenny Heathcote,et al.  Orphanet Journal of Rare BioMed Central Review Primary biliary cirrhosis , 2008 .

[71]  R. Dworkin,et al.  Clinical trial outcome in neuropathic pain , 2008, Neurology.

[72]  K Longley,et al.  EULAR evidence-based recommendations for the management of fibromyalgia syndrome , 2007, Annals of the rheumatic diseases.

[73]  V. Yu,et al.  Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial. , 2008, The journal of pain : official journal of the American Pain Society.

[74]  J. Farrar,et al.  Pharmacologic management of neuropathic pain: Evidence-based recommendations , 2007, PAIN.

[75]  M. Krams,et al.  Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials , 2007, Journal of biopharmaceutical statistics.

[76]  P. Shekelle,et al.  Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society , 2007, Annals of Internal Medicine.

[77]  Xiaohong Huang,et al.  An examination of the efficiency of the sequential parallel design in psychiatric clinical trials , 2007, Clinical trials.

[78]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[79]  M. Max,et al.  Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain , 2007, PAIN.

[80]  Geert Molenberghs,et al.  Missing Data in Clinical Studies , 2007 .

[81]  D. Rubin,et al.  Diagnostics for confounding in PK/PD models for oxcarbazepine , 2007, Statistics in medicine.

[82]  Yoshiaki Matsumoto,et al.  Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. , 2007, Biological & pharmaceutical bulletin.

[83]  Sarah Zohar,et al.  Optimal designs for estimating the most successful dose , 2006, Statistics in medicine.

[84]  Vladimir Dragalin,et al.  Adaptive Designs: Terminology and Classification , 2006 .

[85]  T. Nurmikko,et al.  EFNS guidelines on pharmacological treatment of neuropathic pain , 2006, European journal of neurology.

[86]  C. Schmid,et al.  Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. , 2006, The Journal of rheumatology.

[87]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.

[88]  G. Levy,et al.  A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS , 2006, Neurology.

[89]  H. Sievers,et al.  Efficacy and tolerability of a spray with Salvia officinalis in the treatment of acute pharyngitis - a randomised, double-blind, placebo-controlled study with adaptive design and interim analysis. , 2006, European journal of medical research.

[90]  Andrew P Grieve,et al.  Implementation of a Bayesian adaptive design in a proof of concept study , 2006, Pharmaceutical statistics.

[91]  D. Berry.  Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[92]  Nathaniel Katz.  Methodological issues in clinical trials of opioids for chronic pain , 2005, Neurology.

[93]  M. Max,et al.  Topiramate in chronic lumbar radicular pain. , 2005, The journal of pain : official journal of the American Pain Society.

[94]  D. Tu,et al.  Morphine, gabapentin, or their combination for neuropathic pain. , 2005, The New England journal of medicine.

[95]  J. Farrar,et al.  Core outcome measures for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[96]  J. Stoner.  Cross-over Trials in Clinical Research , 2004 .

[97]  D. Moher,et al.  Turning a blind eye:Testing the success of blinding and the CONSORT statement , 2004, BMJ : British Medical Journal.

[98]  D. Sackett.  Turning a blind eye:Why we don't test for blindness at the end of our trials , 2004, BMJ : British Medical Journal.

[99]  S. Senn.  Turning a blind eye: Authors have blinkered view of blinding , 2004, BMJ : British Medical Journal.

[100]  Jack A. Cook,et al.  The Use of Clinical Trial Simulation to Support Dose Selection: Application to Development of a New Treatment for Chronic Neuropathic Pain , 2003, Pharmaceutical Research.

[101]  David A. Schoenfeld,et al.  The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach , 2003, Psychotherapy and Psychosomatics.

[102]  Christopher Jennison,et al.  Mid‐course sample size modification in clinical trials based on the observed treatment effect , 2002, Statistics in medicine.

[103]  T. Travison,et al.  Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial , 2002, Neurology.

[104]  M. Jensen,et al.  Blinding effectiveness and association of pretreatment expectations with pain improvement in a double-blind randomized controlled trial , 2002, PAIN.

[105]  M. Max,et al.  Dextromethorphan and Memantine in Painful Diabetic Neuropathy and Postherpetic Neuralgia: Efficacy and Dose-Response Trials , 2002, Anesthesiology.

[106]  Christopher L. Wu,et al.  Analgesic Effects of Intravenous Lidocaine and Morphine on Postamputation Pain: A Randomized Double-blind, Active placebo-controlled, Crossover Trial , 2002, Anesthesiology.

[107]  T. Yaksh,et al.  Concentration–effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain , 2001, Pain.

[108]  M. Max,et al.  A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias , 2000, Neurology.

[109]  T. Yaksh,et al.  Concentration–Effect Relationship of Intravenous Lidocaine on the Allodynia of Complex Regional Pain Syndrome Types I and II , 2000, Anesthesiology.

[110]  C. S. Davis,et al.  Threats to the validity of clinical trials employing enrichment strategies for sample selection. , 1998, Controlled clinical trials.

[111]  Adrian Dunne,et al.  Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials , 1997 .

[112]  Stephen Senn,et al.  Statistical Issues in Drug Development , 1997 .

[113]  M. Max,et al.  High‐dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia , 1997, Neurology.

[114]  J. Vanneste,et al.  Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain , 1997, The Lancet.

[115]  M. Rowbotham,et al.  Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia , 1996, Pain.

[116]  M. Byas-Smith,et al.  Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design , 1995, Pain.

[117]  L B Sheiner,et al.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.

[118]  Jon Smith.  Crossover Trials in Clinical Research: By Stephen Senn. John Wiley & Sons Ltd., 1993. pp. xv + 266. £24.95. ISBN 0-471-93493-3 , 1993 .

[119]  Stephen Senn,et al.  Cross-over trials in clinical research , 1993 .

[120]  K. Schechtman,et al.  A comprehensive algorithm for determining whether a run-in strategy will be a cost-effective design modification in a randomized clinical trial. , 1993, Statistics in medicine.

[121]  J. Matthews,et al.  Serial correlation in the design and analysis of crossover trials , 1991 .

[122]  M. Rowbotham,et al.  Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia , 1991, Neurology.

[123]  Klein Df.  Improvement of phase III psychotropic drug trials by intensive phase II work. , 1991 .

[124]  R M Bennett,et al.  The fibromyalgia impact questionnaire: development and validation. , 1991, The Journal of rheumatology.

[125]  D. Klein.  Improvement of phase III psychotropic drug trials by intensive phase II work. , 1991, Neuropsychopharmacology.

[126]  J. Wittes,et al.  The run-in period in clinical trials. The effect of misclassification on efficiency. , 1990, Controlled clinical trials.

[127]  K. Brøsen,et al.  The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms , 1990, Pain.

[128]  M. Kenward,et al.  Design and Analysis of Cross-Over Trials , 1989 .

[129]  R. Dubner,et al.  Amitriptyline, but not lorazepam, relieves postherpetic neuralgia , 1988, Neurology.

[130]  R. Dubner,et al.  Association of pain relief with drug side effects in postherpetic neuralgia: A single‐dose study of clonidine, codeine, ibuprofen, and placebo , 1988, Clinical pharmacology and therapeutics.

[131]  R. Dubner,et al.  Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood , 1987, Neurology.

[132]  R. Dubner,et al.  Suppression of postoperative pain by the combination of a nonsteroidal anti-inflammatory drug, flurbiprofen, and a long-acting local anesthetic, etidocaine. , 1984, Journal of the American Dental Association.

[133]  P. Fox,et al.  Comparison of conorphone, a mixed agonist-antagonist analgesic, to codeine for postoperative dental pain. , 1984, Anesthesia progress.

[134]  David S. H. Bell.  Amitriptyline versus placebo in postherpetic neuralgia , 1983, Neurology.

[135]  H. Merskey,et al.  Amitriptyline versus placebo in post-herpetic neuralgia , 1981, PAIN.

[136]  J. Lellouch,et al.  EXPLANATORY AND PRAGMATIC ATTITUDES IN THERAPEUTICAL TRIALS , 2003 .

[137]  E. Laska,et al.  Oral analgesic studies: Pentazocine hydrochloride, codeine, aspirin, and placebo and their influence on response to placebo , 1966, Clinical pharmacology and therapeutics.